Sara Cunningham
Nurse Practitioner · Ottawa, KSNPI 1447278007
Payments from drug & device makers
Across 217 payments — averaging $17.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$629
- Lilly USA, LLC$394
- Boehringer Ingelheim$370
- AbbVie$316
- Novo Nordisk$276
- Grifols USA, LLC$189
- plus $2K from 43 others
What the payments were for
- Food & beverage$3,70599%
- Education$201%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$3,725 in reported general payments places this provider in the 90th percentile of 1,326 nurse practitioner providers in Kansas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 41 | $36,048 |
| OzempicSemaglutide | 36 | $34,067 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $18,371 |
| MyrbetriqMirabegron | 18 | $11,428 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $10,090 |
| JardianceEmpagliflozin | 15 | $9,531 |
| LinzessLinaclotide | 13 | $7,064 |
| TradjentaLinagliptin | 13 | $6,248 |
| Celecoxib | 40 | $2,410 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 81 | $2,207 |
| Duloxetine Hcl | 68 | $2,065 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 27 | $1,748 |
| Gabapentin | 96 | $1,684 |
| Ventolin HfaAlbuterol Sulfate | 25 | $1,339 |
| Memantine Hcl | 22 | $925 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $30 | $36,04841 claims |
| Novo NordiskOzempic | $276 | $34,06736 claims |
| GSKTrelegy Ellipta | $101 | $18,37118 claims |
| Boehringer IngelheimJardiance, Tradjenta | $370 | $15,77928 claims |
| Astellas Pharma US IncMyrbetriq | $29 | $11,42818 claims |
| AbbVieLinzess | $316 | $7,06413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,326 nurse practitioner providers in Kansas.
Other nurse practitioner in Ottawa
- Gary GrafTopeka$726K
- Sarah FitzmauriceKansas City$247K
- Anna ShortRoeland Park$215K
- Shannon GreggTopeka$140K
- Morteza RabiiOverland Park$88K
- Constance JacobWichita$65K
- Michelle KirkHutchinson$58K
- Catherine PowellWichita$50K
- Lori RanalloWestwood$48K
- Kristyn MilburnPleasanton$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.